Adaptimmune Therapeutics (ADAP) Presents At SITC Virtual Annual Meeting 2020 - Slideshow

Efficacy - Two patients achieved RECIST responses, one with esophagogastric junction (EGJ) cancer and another with head and neck cancer[5, 27] - Initial tumor reductions were observed in 5 out of 6 patients[5, 25, 27] - The data supports further investigation of ADP-A2M4CD8 as an active product[4, 27] Safety - All 6 patients (100%) experienced adverse events (AEs), with all 6 (100%) having Grade ≥3 AEs[14] - Common AEs (any grade) included leukopenia, lymphopenia/lymphocyte decrease, and neutropenia/neutrophil decrease, each occurring in 6 patients (100%)[14] - Other frequent AEs (any grade) were anemia/red blood cell decrease (4 patients, 67%), cytokine release syndrome (4 patients, 67%), fatigue (4 patients, 67%), headache (4 patients, 67%), and nausea (4 patients, 67%)[14] - One serious adverse event (SAE) of cytokine release syndrome was reported in a patient in Cohort 2 and was considered related to the T-cell infusion[15] - Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or cancer immunotherapy[5, 15, 26] Trial Design and Next Steps - The SURPASS trial is a first-in-human dose-escalation trial[8] - The trial is focusing on enrolling patients with gastroesophageal, head and neck, lung, and bladder cancers[5, 7, 28] - A Phase 2 trial is planned for 2021 with ADP-A2M4CD8 in patients with gastroesophageal cancers[5, 7, 17, 28]